What is Wellpartner?
Founded in 2000, Wellpartner offers comprehensive 340B program management solutions, leveraging innovative technology and URAC-accredited specialty pharmacy services. The company is dedicated to assisting healthcare organizations navigate the intricacies of the 340B Drug Program, providing services such as compliance management, specialty network access, and claims capture optimization. Wellpartner's integrated approach combines retail pharmacy expertise with advanced technological capabilities to help covered entities conserve resources while effectively serving patient populations in need.
How much funding has Wellpartner raised?
Wellpartner has raised a total of $37.6M across 3 funding rounds:
Series B
$14M
Series C
$7.5M
Series D
$16.1M
Series B (2005): $14M with participation from Scorpion Capital Partners
Series C (2007): $7.5M led by 3i Group, Greenwoods Asset Management, Montlake Capital, Integra Ventures, and Mediphase Venture Partners
Series D (2008): $16.1M supported by Mediphase Venture Partners, 3i Group, Integra Ventures, Montlake Capital, and Greenwood Management
Key Investors in Wellpartner
Mediphase Venture Partners
Mediphase Venture Partners is a venture capital firm that focuses on health care and life sciences companies, seeking those with outstanding market opportunities and rapid growth potential. They actively engage with portfolio companies, often joining boards to support management in achieving rapid growth.
3i Group
3i is an investment company specializing in Private Equity and Infrastructure, with a focus on mid-market companies in northern Europe and North America. They invest in businesses to drive growth and value creation.
Integra Ventures
Integra Ventures is a leading healthcare consulting firm that provides strategic, financial, and operational solutions for healthcare providers. They specialize in enhancing healthcare infrastructure and IT services, supporting both public and private sector initiatives.
What's next for Wellpartner?
The recent major strategic investment in Wellpartner signals a pivotal moment for the company, likely enabling further expansion of its technological infrastructure and service offerings. This capital will be instrumental in enhancing its 340B program management solutions, potentially broadening its reach to more healthcare organizations and reinforcing its commitment to compliance and patient care. The company's established history of securing substantial funding rounds suggests a strategic focus on scaling operations and solidifying its market leadership in the specialized pharmacy services sector.
See full Wellpartner company page
